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A B S T R A C T
The aﬀordable and reliable detection of Hepatitis C Virus (HCV) RNA is a cornerstone in the management and
control of infection, aﬀecting approximately 3% of the global population. However, the existing technologies are
expensive, labor intensive and time consuming, posing signiﬁcant limitations to their wide-scale exploitation,
particularly in economically deprived populations. Here, we utilized the unique optical and physicochemical
properties of gold nanoparticles (AuNPs) to develop a novel assay platform shown to be rapid and robust in
sensing and quantifying unampliﬁed HCV RNA in clinical samples. The assay is based on inducing aggregation
of citrate AuNPs decorated with a speciﬁc nucleic acid probe. Two types of cationic AuNPs, cysteamine and
CTAB capped, were compared to achieve maximum assay performance. The technology is simple, rapid, cost
eﬀective and quantitative with 93.3% sensitivity, high speciﬁcity and detection limit of 4.57 IU/µl. Finally, our
data suggest that RNA folding impact the aggregation behavior of the functionalized AuNPs, with broader
applications in other nucleic acid detection technologies.
1. Introduction
Approximately 3% of the world population are infected with
hepatitis C virus (HCV) with 3–4 million infections annually and at
least 150 million chronic carriers at risk of developing liver cirrhosis
and/or liver cancer (WHO, 2016). It was estimated that more than 15%
of the Egyptian population are currently infected with HCV
(Hajarizadeh et al., 2013; Mauss et al., 2013) with almost half million
new cases arising annually. The infection usually progresses to fatty
liver and hepatocellular carcinoma, posing signiﬁcant health and
economic challenges to the society (Miller and Abu-Raddad, 2010).
Since an approved vaccination against HCV is yet to be established (Lee
et al., 2015; WHO, 2016), the prime combating strategies rely on newly
developed medications coupled to robust and aﬀordable means of viral
detection and quantiﬁcation (AASLD-IDSA, 2016; Seifert et al., 2015).
HCV diagnosis is achieved by serologic and Nucleic Acid Testings
(NATs) (Scott and Gretch, 2007). A major drawback of the serological
approach is the inability to detect acute infections (Cloherty et al.,
2016) and the associated complications of immuno-suppression pa-
tients (Atrah and Ahmed, 1996; Mauss et al., 2013). NATs are based
mainly on Real-Time RT-PCR, branched- DNA (b-DNA), and tran-
scription-mediated Ampliﬁcation (TMA). NATs are relatively expen-
sive, labor intensive, and require adequately equipped labs, posing
signiﬁcant limitations to their point of care testing. Thus, alternative
approaches for HCV RNA detection and quantiﬁcation are urgently
needed.
The unique optical properties of gold nanoparticles (AuNPs), were
originated from their strong Surface Plasmon Resonance (SPR) phe-
nomena, which is responsible for their intense colors, and high
extinction coeﬃcient compared to conventional dyes (Huang et al.,
2007a). Thus, AuNPs have been employed in many colorimetric assays
for diﬀerent biological molecules as proteins (Kim et al., 2009), and
nucleic acids (Liandris et al., 2009). For example, Mirkin and co-
workers were the ﬁrst to develop a modiﬁed AuNPs cross-linking
method for the direct detection of nucleic acids (Elghanian et al., 1997;
Larguinho et al., 2015). Despite the high sensitivity and speciﬁcity of
this method, it requires ﬁrm temperature control for precise target
detection. To our knowledge, this method has not been used for nucleic
acids detection clinically. Li and co-workers developed a method for the
direct detection of nucleic acids using unmodiﬁed AuNPs (Li and
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Rothberg 2004a, 2005). The technique is based on the adsorption
behavior of single and double stranded nucleic acid onto AuNPs surface
and the medium ionic strength. Despite its sensitivity and speciﬁcity, it
requires precise control of the probe, salt, and AuNPs concentrations.
The non-cross linking method was ﬁrst introduced by Sato and co-
workers (Sato et al., 2003), which is based on functionalizing AuNPs
with single stranded thiol-modiﬁed probe. AuNPs aggregation is based
also on the ionic strength of the medium. However, the desired results
Fig. 1. A scheme depicting the nano-assay principle and procedures. (1) Citrate capped AuNPs, was functionalized with thiolated HCV speciﬁc probe forming nanoprobes. (2) The
nanoprobe is then mixed with the RNA sample and heated at 95 °C for 3 min. (3) Right panel; the HCV viral RNA was hybridized to the HCV speciﬁc nanoprobe by sequence
complimentarily. Left panel; no HCV RNA is present (non-speciﬁc RNA target), thus no hybridization takes place. The mixture incubated at room temperature. (4) The cationic AuNPs
was added. (5) Right panel; in the presence of HCV RNA, the mixture solution remains red, reﬂecting the dispersion of the AuNPs onto the folded HCV RNA, thereby protecting the
nanoprobes from aggregation by cationic AuNPs. Left panel; in the absence of a complementary target, the cationic AuNPs will bind to the probe phosphate backbone electrostatically,
thereby reducing the inter-particle distance between the nanoprobes and the cationic AuNPs, resulting in aggregation and color change from red to blue. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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are only achieved if the target is of the same length as the probe.
Baptista and co-workers improved this technique to detect long nucleic
acids; however it still depends on either high ionic strength or the pH
to induce AuNPs aggregation (Baptista et al., 2008; Larguinho, Canto
et al., 2015).
Herein, we utilized positively charged gold nanoparticles (cystea-
mine and CTAB AuNPs) to induce aggregation of citrate capped AuNPs
decorated with an HCV RNA speciﬁc probe (Graphical abstract and
Fig. 1). Our aim was to minimize the factors that may aﬀect the output
results, enhance the speciﬁcity, sensitivity and detection limit. Most
importantly, this approach allowed us to achieve quantitative detection
of HCV RNA in clinical samples, in short time and with reasonable cost,
and it could be easily adapted for full automation. Furthermore, the
nano-assay was validated using other RNA transcripts extracted from
cell lines to illustrate its broad utility as a nucleic acid detection
technology.
2. Materials and methods
2.1. Chemicals and equipments
Hydrogen tetracloroaurate (III) trihydrate (HAuCl4·3H2O) ˃99%,
Dithiothrietol, Dibasic and mono basic phosphate, Sodium dodecyl
sulfate (SDS), Sodium Chloride, Sodium borohydride,
Hexadecyltrimethyl ammonium bromide (CTAB), Tri-sodium citrate
dehydrate, and Ribonuclease A were purchased from Sigma- Aldrich.
Cysteamine (2-Mercaptoethylemine HCl ˃98% was purchased from
Acros Organics). SV-Total RNA isolation system was purchased from
Promega. Artus HCV RG RT-PCR Kit and QIAmp viral RNA kit were
purchased from Qiagen. RPMI-1640 medium, L-glutamine, Penicillin/
streptomycin was purchased from Lonza, while fetal bovine serum
from Gibco. NAP-5 columns (illustra NAP-5, GE Healthcare).
UV–vis spectra were recorded with Eppendorf Bio-spectrophot-
ometer basic. A zetasizer ZC system (Malvern Instrument Ltd., Zeta
sizer Nano series, UK) was used for size and potential measurements.
High resolution transmission electron microscope (HRTEM, JEM-
2100) was used for imaging
2.2. Serum samples collection
Sample Collection was done following ethical approval and in-
formed consent of all subjects. HCV infected serum samples were
collected (n=28), which included 23 samples with chronic HCV
infection and 5 samples with acute HCV infection. Healthy volunteers
provided 17 serum samples. Rapid HCV and Hepatitis B virus (HBV)
antibody tests were performed for all samples. Only one sample was
HBV positive. Real-time PCR was conducted for all the samples using
Artus HCV RG RT-PCR Kit according to the manufacturers’ instruc-
tions.
2.3. Synthesis, functionalization and characterization of citrate
AuNPs and nanoprobes
Citrate AuNPs was prepared by the traditional sodium citrate
reduction method of Gold (III) chloride (Hill and Mirkin, 2006;
Turkevich, 1985a, 1985b). Characterization was done using
Transmission Electron Microscope (TEM), UV–Vis. spectroscopy and
Dynamic light scattering (DLS). Citrate AuNPs were functionalized
with each alkanethiol modiﬁed RNA target speciﬁc probe using well
known salt aging process (Hurst et al., 2006). Functionalization of the
alkanethiol probes was done exactly as described (Hill and Mirkin,
2006). HCV speciﬁc probe is an antisense primer of 32 bases
complementary to the highly conserved region in the HCV RNA 5′-
untranslated region (5′UTR) in almost all genotypes and subtypes. The
probe (5′-TACCACAAGGCCTTTCGCGACCCAACACTACT’-3) was al-
kane-thiol modiﬁed at its 5′-terminus. In parallel reactions, functio-
nalization was performed for Topoisomerase 1 & 2 (TOP1 and &
TOP2), Tyrosyl- DNA phosphodiesterases 1 & 2 (TDP1 and TDP2)
transcripts, by alkanethiol speciﬁc probes for each transcript extracted
from Rectal Cancer carcinoma (RKOs) cell lines. Each transcript
speciﬁc probe was functionalized to the AuNPs solution separately.
2.4. Synthesis and characterization of Cysteamine AuNPs
Cysteamine AuNPs were synthesized using sodium borohydride
reduction method as described (Kim, Kim et al., 2009). Cysteamine
AuNPs was characterized using TEM, DLS, and spectrophotometri-
cally.
2.5. Synthesis and characterization of CTAB AuNPs
CTAB AuNPs synthesis is generally performed following the
established seed-mediated growth using two solutions (El-Sayed
et al., 2006; Huang et al., 2007b; Li et al., 2013; Scarabelli et al.,
2015). Herein, CTAB AuNPs was synthesized using only the seed
solution in a single-phase reaction without the growth solution. In a
typical experiment, 3.7 ml of 0.2 M aqueous solution of CTAB was
mixed with 20 µl of 1 mM gold chloride under vigorous stirring at
50 °C. Then, 1 ml of ice-cold 10 mM sodium borohydride was added in
three portions with 20 min intervals. Solution color was changed from
yellow to light brown after the ﬁrst addition of the borohydride and
color intensity increased after each addition. Stirring was continued for
3 h at 50 °C and then stored at room temperature for 2 days at dark. A
clear pink-colored solution was obtained after two days, which is
followed by characterization as described above for AuNPs.
2.6. HCV RNA extraction evaluation
HCV RNA extraction was performed using Promega SV-total RNA
isolation system according to the modiﬁed HCV extraction manufac-
turer's protocol (Otto et al., 1998). The QI-Amp Viral RNA kit was used
for HCV RNA extraction to select the best RNA extraction kit
compatible with the nano-assay.
2.7. Cell lines and total RNA extraction
RKOs cancer cell lines (Homo sapiens, Tissue: colon, Carcinoma)
were cultured at 37 °C and 5% CO2 in RPMI-1640 medium, supple-
mented with 10% fetal bovine serum, 1% L-glutamine and 1%
penicillin/streptomycin. Total RNA extraction was conducted using
Promega SV-total RNA isolation system following manufacture in-
structions and each transcript was further puriﬁed by homemade
magnetic nanoparticles as described previously (Eissa et al., 2014;
Shawky et al., 2014), to enhance the purity of the extracted transcript.
2.8. Colorimetric/spectrophotometric AuNPs assay for RNA detection
The assay was performed by mixing 5 µl of nanoprobe with 10 µl of
RNA sample, heated at 95 °C for 3 min, incubated at room temperature
for 5–10 min. Cationic AuNPs (10 µl) was then added to the solution
and mixed well. Solution color was developed immediately and
observed by naked eye while mixing. The color was stable for
~30 min, depending on the RNA concentration. Solutions were
scanned from 400 nm to 750 nm using spectrophotometer. To conﬁrm
that the color change is due to RNA solely, the nano-assay was
performed on two HCV positive samples before and after digestion
with Ribonuclease A enzyme. Each sample was divided into two
portions, one portion was treated with the enzyme by adding 10 µl of
10 mg/ml Ribonuclease A to 35 µl of HCV RNA and then incubated for
20 min at room temperature. After completion of the digestion process,
the assay was performed on the Ribonuclease A treated sample and on
the mock-treated sample. The color of the two samples was then
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observed and samples were also analyzed using TEM.
2.9. Quantiﬁcation of HCV RNA using real-time RT-PCR and the
developed nano-assay
HCV RNA viral load was determined using Artus Qiagen HCV Real-
time RT-PCR Kit, according to the manufacturer manual, for all sera
samples. Quantiﬁcation of HCV RNA using the nano-assay was
performed by preparing serial dilutions of HCV RNA concentration
(10–1200 IU/µl), and examined using the nano-assay. The spectral
absorbance for each concentration was scanned spectrophotometrically
in duplicate, and the ratio of the non-aggregated nanoparticles at λ530
to the aggregated nanoparticles at λ650 (A530/ A650) was recorded and
used to generate the standard curve, in which the A530/ A650 ratio was
plotted against the viral RNA log concentration. All HCV RNA samples
viral load were determined by the nano-assay using the generated
standard curve, from their respective A530/ A650 ratios, using the
equation generated by the standard curve.. The results were expressed
in IU/µl and converted to IU/ml by (IU/µl *RNA elution volume in µl/
serum volume in µl). Comparison between the developed nano-assay
and the Real-Time RT-PCR viral load is shown in Table S1, and
Fig. 6c–f. Receiver operating characteristic curve (ROC curve) for the
nano-assay was generated to determine the speciﬁcity, sensitivity, and
the detection limit (Table S2), using SPSS software (IBM, SPSS
Statistics, version 20 package). Detection limit was further conﬁrmed
by performing serial dilutions of HCV sample till 1 IU/µl. Each dilution
was tested by the nano-assay until aggregation occurred starting from
about 4 IU/µl.
2.10. Nano-assay TEM analysis for positive, and HCV negative
samples, and Ribonuclease A treated sample before and after
digestion
TEM analysis was conducted immediately after performing the
nano-assay for both HCV positive and negative samples. Moreover, it
was performed on the Ribonuclease treated and mock-treated sample
as described in Section 2.8 to verify that RNA folding contributes to
nanoprobe stability.
3. Results and discussion
3.1. Citrate AuNPs synthesis, functionalization and characterization
Citrate AuNPs morphology were characterized by TEM analysis. As-
synthesized AuNPs were spherical and uniformly distributed with
average diameter of ~20 nm (Fig. 2a) and average charge of −48 mv.
Size and the charge were further measured using DLS (Fig. S1a and b).
HCV nanoprobe was synthesized by functionalization of the Citrate
AuNPs with the alkanethiol modiﬁed probe. Functionalization exploits
the thiol group, which possesses a higher aﬃnity to the gold surface
than citrate, thereby forming a strong covalent bond (Xue et al., 2014),
providing high stability to the nanoprobe against high salt, and positive
ligands concentrations induced aggregation. TEM analysis of HCV
nanoprobe revealed an increase in the citrate AuNPs from ~20 nm to
~38 nm (Fig. 2b), which was conﬁrmed by DLS with a corresponding
reduction of surface charge from −48 mv to −27 mV (Fig. S2a and b).
Spectrum of the as-synthesized AuNPs revealed a λmax at 520 nm, while
that of the nanoprobe showed a slight red shift to 530 nm (Fig. 2c). The
red shift was accompanied by a noticeable absorption broadening upon
cysteamine AuNPs induced aggregation of the nanoprobe (Fig. 2c).
Molar concentration of AuNPs was calculated to be 4 nM with
~2.436×1012 nanoparticles per ml (Liu et al., 2007). Together, these
data demonstrate proper conjugation of probes to the particles and
conﬁrm the ability of cysteamine AuNPs to induce aggregation of the
nanoprobe.
The probe amount and density conjugated to citrate AuNPs are
crucial for downstream applications. At high amount, steric hindrance
at the AuNPs surface takes place, resulting in electrostatic repulsion
between the target and the probe, and thus no hybridization takes place
(Doria et al., 2010). It was estimated that ~1.44 nmol probes were
conjugated to the AuNPs. Accordingly, the amount of probes per one
nanoparticle was ~120 oligonucleotides, which is in agreement with
previously reported functionalization methods (Hurst et al., 2006).
3.2. Cysteamine and CTAB AuNPs synthesis and characterization
CTAB and cysteamine AuNPs morphology were characterized using
TEM (Fig. 3a and b, respectively). Cysteamine AuNPs was spherical
and uniformly distributed with an approximate size of 40 nm and a
λmax of ~528 nm (Fig. 3c), with an average positive charge of +39. The
uniformity and charge were further assessed by DLS (Fig. S3a and b).
The Molar concentration was calculated as described (Liu et al., 2007)
and found to be ~0.5 nM with ~3.04×1011 nanoparticles per ml. The
charge and size of CTAB AuNPs were +100 mv and 30 nm, respectively
(Fig. S4a and b). CTAB AuNPs extinction spectrum revealed one sharp
peak in the visible region with λmax at 526 nm, suggesting spherical
nanoparticles with uniform size (Fig. 3c). However, their TEM analysis
(Fig. 3a) showed core/shell like structure of many AuNPs coated within
a shell. This is may be due to AuNPs seeds formation followed by their
internalization within the CTAB micelle. We propose that synthesis of
CATB AuNPs from seed solution only is primarily aﬀected by reagent
concentrations, especially the reductant to the gold precursor, which
was increased by ~450 times, and the CTAB which was increased by
two times, compared to conventional methods (Orendorﬀ and Murphy,
2006). Once the seeds are formed in the presence of the high
concentration of CTAB and reaction high temperature that stabilized
the CTAB micelles and preserved the particles from aggregation, it led
to extra layers on the nanoparticles, which appeared as a shell like
structure (Fig. 3a). Moreover, the addition rate of the reductant (3
times with 1 h intervals) and its high concentration led to complete
reduction of all the gold ion states to gold metal. Indeed, the high
reaction temperature aﬀects the ﬁnal AuNPs shape and size (Scarabelli
et al., 2015). Thus, the high temperature employed here and long
growth time (2 days) led to further growth of the traditional seed
particles into bigger nanoparticles and prevented the CTAB molecules
from crystallization.
3.3. Selection of cysteamine AuNPs for the nano-assay
We noticed higher degree of aggregation and broader spectra of
CTAB-AuNPs than cysteamine-AuNPs when incubated with either
HCV RNA or control samples (Fig. 4a). Spectral behavior of CTAB
AuNPs on HCV positive samples was closely similar to that produced
with monovalent or divalent cations in the conventional non-cross
linking assays (Conde et al., 2010). This is likely due to the highly stable
positively charged quaternary ammonium (NH4
+) cation, which ulti-
mately increases false negative possibilities. Therefore, we decided to
use cysteamine-AuNPs that are capable of acting as hydrogen bond
donors/acceptors towards the nanoprobe-HCV RNA. This also led to
improved color detection since CTAB AuNPs colors were fainter
(Fig. 4b) compared to cysteamine AuNPs (Fig. 4c) in both positive
and negative samples.
3.4. Evaluation of diﬀerent RNA extraction Kits
Total RNA Promega Kit was chosen for RNA extraction. Selection of
Promega Kit over the Qiagen viral RNA extraction kit was based on that
the high rate of false positives recovered with the latter. This is likely
due to DNA contamination hence the kit was not designed to separate
viral RNA from cellular DNA (Qiagen, 2014). The presence of
circulating cell free DNA in the serum with high concentration along
with some genomic DNA in the ﬁnal product had negative impact on
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assay performance, masking the nanoprobe from aggregation and
increases false positive outcomes. In contrast, Promega total RNA
isolation kit includes a DNase treatment step, which eliminates DNA
from the ﬁnal product, providing pure RNA with reproducible results.
3.5. Factors aﬀecting nano-assay performance
The nano-assay reproducibility, sensitivity and speciﬁcity are
primarily aﬀected by (1) nanoprobe and cationic AuNPs concentration
and type, (2) pH of the reaction mixture, (3) temperature and (4) RNA
folding. The nanoprobe density of ~120 probes per small sized AuNPs
~20 nm is known to improve its stability against aggregation and
provides acceptable amount for proper probe/RNA hybridization
(Hurst, Lytton-Jean et al., 2006). Final nanoprobe and cationic
AuNPs concentrations greatly aﬀected the nano-assay ﬁnal results.
The expected outcome was observed when CATB AuNPs concentration
was less than nanoprobe concentration. However, higher concentration
of CTAB AuNPs caused nanoprobes aggregation even in the presence of
the RNA, likely due to the CTAB strong positively charged quaternary
ammonium cation. In contrast, cysteamine AuNPs gave superior
results regardless of the cysteamine AuNPs or nanoprobe concentra-
tion. The best results obtained when cysteamine AuNPs was twice the
nanoprobe amount. Moreover, the spectrum of samples following
cysteamine AuNPs had sharp peaks and showed a clear diﬀerence
between the positive and negative samples. This allowed a linear
relation to be devised and thus enabled quantitative detection of
RNA. In contrast, CTAB AuNPs spectra were not clear enough to
diﬀerentiate between diﬀerent RNA concentrations and thus couldn't
be used for quantitation. Comparison between the two cationic AuNPs
regarding the absorption peaks and color intensity of the nano- assay is
shown in Fig. 4a–c. Key to this enhanced performance is most likely
that cysteamine short molecular dimension, which allowed better
distribution on the folded HCV RNA backbone.
Solution pH had no impact on the nano-assay as the CTAB AuNPs
quaternary ammonium group is always positively charged regardless of
the pH while the cysteamine protonated amino group positive charge
predominates from pH 9.3, which is way above the assay pH at 7.4. The
non-pH dependency of our assay is superior to the non-cross linking
assays described previously where pH is a main player for assay
performance, especially in the target/mismatched probes (Sato et al.,
2005). Therefore, using cationic AuNPs excludes the pH parameter
from the assay. The last two parameters aﬀecting assay performance
are reaction temperature and nucleic acid folding. Reaction tempera-
ture highly aﬀected the nano-assay. Immediate aggregation has
Fig. 2. Characterization of citrate-capped AuNPs. (a) A representative TEM image of the citrate-capped AuNPs (b) and of the nano-probe (c). The spectra of the citrate capped AuNPs
showing SPR λmax at approximately 520 nm. The nanoprobe showed a slight red shift to 530 nm with a decrease in the peak intensity indicating functionalization. Cysteamine AuNPs
induced aggregation of the nanoprobe spectrum was shown by brooding in its peak and the lack of SPR.
Fig. 3. Characterization of CTAB and Cysteamine AuNPs. (a) TEM image of CTAB AuNPs showing the nanoparticles appearing as clusters of small AuNPs surrounded or internalized
within a shell. (b) TEM image showing Cysteamine AuNPs. (c) The extinction spectra of the cysteamine AuNPs and CTAB AuNPs shows λmax of 528 and 526 nm; respectively.
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occurred upon mixing the nanoprobe with the cationic AuNPs even
with very high RNA concentrations. This is due to electrostatic
interaction aﬃnity between the probes’ nitrogenous bases and the
citrate AuNPs, which prevents hybridization between the RNA target
and the probes (Li and Rothberg 2004b). A brief denaturation step was
therefore conducted for the nanoprobe/RNA mixture and prior to the
addition of the cationic AuNPs to allow accessibility of the probes to the
RNA molecules (Larguinho et al., 2015), and thus allowing for the
unfolding of the RNA tertiary structure and subsequent hybridization
with its complementary probes. Incubation of the mixture at room
temperature prior to the addition of the cationic AuNPs was essential.
The time/temperature gap between heating and the addition of cationic
AuNPs allowed for RNA hybridization to the probe and subsequent
RNA re-folding to adopt its most thermodynamically stable form
(Doerrbecker et al., 2013; El Awady et al., 2009).
We propose RNA folding adaptation to coat the nanoprobe after
hybridization, resulting in multiple layers of RNA, thereby stabilizing
the nanoprobe. The shape adopted by the re-folded RNA is predicted to
give high surface area for the cationic AuNPs to be distributed along the
RNA molecules, preventing its interaction with the nanoprobe and
preserving their distribution. This notion was conﬁrmed by comparing
TEM results for HCV positive and negative samples (Fig. 5a and b). To
further validate the assay, HCV samples were re-analyzed with and
without prior digestion with RNase A. In RNase A treated samples,
aggregation of the AuNPs occurred, as was the case for negative
samples, indicating absence of RNA. In contrast, in mock treated
samples the stability of AuNPs was noticeable with a detectable red
color (Fig. 4d), which was further conﬁrmed by TEM (Fig. 5c and d).
3.6. Quantitative determination of HCV RNA in serum samples using
the nano-assay
As the concentration of the RNA increased the nanoprobe λmax
height at wavelength 530 nm proportionally increased, representing
the non-aggregated AuNPs (dispersed nanoparticles, Fig. S6a). The
opposite occurred as the RNA concentration decreased, the nanoprobe
λmax height declined with concomitant shift and broadness in the peak
to a higher wavelength, indicating an increase in the aggregated AuNPs
population (non-dispersed AuNPs). Thus, at high RNA concentration
the ratio of the non-aggregated/aggregated is high, indicating the
predominance of the dispersed nanoprobes and their stability and vice
versa. The standard curve (Fig. S6b) was plotted by recording the
spectral absorbance at λ530/λ650 ratio against RNA log concentration.
The plot showed a linear relation (Y=1.1143x+1.1066, R2=0.97). All
sample concentrations were calculated using the standard curve and
ratio described above. Also, some samples with diﬀerent concentra-
tions were plotted on the standard curve in Fig. S7, and a linear
relation has been obtained (Y=1.2008x+1.0055, R2=0.966). All sam-
ples quantiﬁed by the nano-assay were compared to the gold standard
Real-Time RT-PCR method for HCV quantiﬁcation (Table S1). The
Real-Time RT-PCR revealed 27 out of the 28 as positive HCV samples,
whereas the nano-assay revealed 26 out of 28 as positive with a
Fig. 4. Analyses of HCV clinical samples using cysteamine and CTAB AuNPs. (a) Extinction spectra of positive and negative HCV samples detected by the cysteamine and CTAB AuNPs.
Note the diﬀerence in the peak intensity between the two cationic AuNPs used. Cysteamine AuNPs showed better SPR and well deﬁned peak than the CTAB AuNPs. In contrast to CTAB
AuNPs, no signiﬁcant diﬀerence between the SPR of cysteamine AuNPs in the positive sample compared to the nanoprobe peak was observed. (b) A representative photograph showing
the change in color using CTAB AuNPs biosensors. We note the faint colors of both the positive and negative samples. (c) A representative photograph showing the change in color using
cysteamine AuNPs biosensors. Note the brighter colors produced compared to CTAB AuNPs biosensors. (d) The assay was performed on HCV positive sample with and without the
addition of Ribonuclease A (RNase A). While the tube on the right showed faint red color indicating the presence of HCV RNA, the faint color is due to the sample was diluted before
photographing, for proper comparing with the other tube. The RNase A treated tube on the left was nearly colorless indicating the absence of RNA. The diﬀerence in color conﬁrms that
the HCV RNA accounts for the stability of the AuNPs solution. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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concordance of ~96.3%. Three out of the 17 HCV-negative samples
were detected as HCV-positive by the qRT-PCR. Surprisingly, the same
three samples were detected as HCV-positive by the nano-assay so the
concordance with the qRT-PCR in the negative samples was 100%.
These three samples were negative by an HCV RNA rapid antibody
detection test but were found positive by an ELISA assay. Moreover,
HCV anti-IgM was negative and consequently these three samples were
classiﬁed in this study as asymptomatic chronically HCV infected. After
including the three samples as HCV positive the assay speciﬁcity
increased to 100% instead of 94.1% and sensitivity increased to
93.3% instead of 89.3% at detection limit 4.57 IU/µl.
3.7. Charge and size of diﬀerent AuNPs and comparison between
real-time RT-PCR and the nano-assay
HCV positive samples charge was negative indicating the distribu-
tion and spreading of cationic AuNPs along the RNA molecules,
thereby preventing the aggregation of the nanoprobe (Fig. 6a and
S5a, right panel). In contrast, HCV negative samples (aggregated
AuNPs) were positively charged indicating the alignment of the cationic
AuNPs onto the nanoprobe phosphate backbone, and reduction of the
inter-particle distance between the nanoprobes and the cationic AuNPs
(Fig. 6a and S5b, right panel). It was associated with a reduction in
inter-particle distance leading to increase in the size to ~900 nm
(Fig. 6b and S5b, left panel). However, the HCV positive sample size
increased to ~190 nm (Fig. 6b and S5a, left panel), which is likely due
to diﬀerences in the amount of the dispersed to non-dispersed AuNPs,
which depends mainly on the RNA concentration of the tested sample.
Finally, we examined whether the nano-assay could also be applied to
other RNAs from diﬀerent sources (e.g. cell lines). Four RNA tran-
scripts implicated in the repair of protein-linked DNA breaks were
tested using speciﬁc nanoprobes for each transcript (Ashour et al.,
2015, Elsayed et al., 2016, Meisenberg et al., 2016). In agreement with
HCV detection, the results of the additional four transcripts conﬁrm the
broad utility of the biosensor technology in RNA detection (Fig. S8). A
summary of the size and charge of nanoparticles, and a comparison
between the Real Time RT-PCR and the nano-assay are depicted in
Fig. 6.
4. Conclusions
We developed a novel AuNPs quantitative biosensor colorimetric
assay for the direct detection of unampliﬁed HCV RNA in clinical
samples and DNA repair transcripts from cell lines. Stability or
aggregations of the nanoprobes rely on cationic AuNPs and RNA target
folding rather than the medium ionic strength or pH, which limits false
positives. The assay is simple with a turnover time of ~30 min
including RNA extraction, sensitive, speciﬁc, cost eﬀective and could
readily be adopted for full automation.
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Fig. 5. Characterization of AuNPs in the presence of HCV RNA. (a) Representative TEM images for HCV positive samples after performing the assay showing the distribution of the
nanoparticles (black spheres) along and within the RNA molecules and in solution. The RNA folding protects the nanoprobe from aggregation and provides a large surface area for the
cationic AuNPs to be distributed on. (b) Representative TEM images showing the aggregation of the nanoparticles in absence of HCV RNA. The inter-particle distance between the
AuNPs decreases and thus induces aggregation. (c) TEM images for another HCV positive sample after performing the assay, which is consistent with images in panel a. (d) The same
sample was subjected to the developed nano-assay after treatment with Ribonuclease A. Note that digestion of RNA molecules caused aggregation of the AuNPs with some residues of
RNA whereas the RNA negative sample also showed aggregation with no residual RNA.
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Supplementary data associated with this article can be found in the
online version at doi:10.1016/j.bios.2016.11.001.
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Fig. 6. Summary of the size and zeta potential, and a comparison between the Real Time RT-PCR and the nano-assay. (a) Charges of all AuNPs used in this study. HCV negative samples
have positive charge while HCV positive samples have negative charge. (b) The size of the diﬀerent AuNPs preparations and the HCV positive & negative samples. A signiﬁcant size
increase for the negative samples was observed that conﬁrms the aggregation of the nanoparticles. The mild increase in size of the positive sample may be due to a slight aggregation of
some nanoparticles in the reaction mixture, which is not signiﬁcant as the color of the sample did not change and was dependent on RNA concentration. (c) The mean viral loads (IU/ml)
and standard deviations for the samples tested using the nano-assay (15203 ± 1898) and the RT-PCR (15203 ± 1898) respectively, showing no signiﬁcant diﬀerence in the ﬁnal viral load
between the two methods. (d) The nano-assay showed a sensitivity and speciﬁcity of 93.3% and 100%, while RT-PCR showed a 96.8% sensitivity and 100% speciﬁcity . (e) The
overall time of the nano-assay for one sample was ~30 min compared to 230 min for the RT PCR (f) Cost per sample for the developed biosensor and the RT PCR was 4.5 and 33 USD,
respectively; cost including all materials, chemicals and plastics used for the assays, and the RNA extraction cost. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article).
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